

SAFETY DATA SHEETS

This SDS packet was issued with item:

078359099

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078359073 078359081 078592976



SAFETY DATA SHEET

CLINTABS® Tablets

1. IDENTIFICATION

Product Name	CLINTABS® Tablets
Recommended use of the chemical and restrictions on use	
Identified uses	Antibiotic for use in dogs
Restrictions on Use	Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Company Identification	Virbac AH, Inc. P.O. Box 162059 Fort Worth, Texas 76161 (800) 338-3659
Customer Information Number	
Emergency Telephone Number	
Chemtrec Number	(800) 424-9300
Other Emergency Number:	Human Toll-free 833-224-2009 Animal Toll-free 833-224-2013
Issue Date	March 2, 2020
Supersedes Date	February 6, 2017

Safety Data Sheet prepared in accordance with OSHA's Hazard Communication Standard (29 CFR 1910.1200) and the Globally Harmonized System of Classification and Labelling of Chemicals (GHS)

2. HAZARDS IDENTIFICATION

Hazard Classification

This product is classified as not hazardous in accordance with the Globally Harmonized System of Classification and Labelling (GHS).

Label Elements

Hazard Symbols
None

Signal Word: None

Hazard Statements

None

Precautionary Statements

Prevention

None

Response

None

Storage

None

Disposal

None

Other Hazards

None



2. HAZARDS IDENTIFICATION

Specific Concentration Limits

The values listed below represent the percentages of ingredients of unknown toxicity.

Acute oral toxicity	<10%
Acute dermal toxicity	60 - 70%
Acute inhalation toxicity	>90%
Acute aquatic toxicity	>90%

3. COMPOSITION/INFORMATION ON INGREDIENTS

Synonyms:

This product is a mixture.

Component Name	CAS Number	Concentration
Clindamycin Hydrochloride	58207-19-5	40 - 50%

4. FIRST AID MEASURES

Description of necessary first-aid measures

Eyes

Not an expected route of entry. If tablet contacts eye, flush thoroughly with water. If pain or irritation persists contact a physician.

Skin

If irritation develops wash skin thoroughly with soap and water. Obtain medical attention if redness or soreness persists.

Ingestion

Call a poison control center or doctor immediately for treatment advice. Do not induce vomiting unless told to do so by a poison control center or doctor. Do not give anything by mouth to an unconscious person.

Inhalation

Remove person to fresh air. Seek medical attention if symptoms persist.

Most important symptoms/effects, acute and delayed

Aside from the information found under Description of necessary first aid measures (above) and Indication of immediate medical attention and special treatment needed, no additional symptoms and effects are anticipated.

Indication of immediate medical attention and special treatment needed

Notes to Physicians

Treat symptomatically.

5. FIRE - FIGHTING MEASURES

Extinguishing Media

Use extinguishing media appropriate for surrounding materials.

Unusual Fire and Explosion Hazards

Can release hazardous vapors during a fire.

Protective Equipment for Fire-Fighting

Wear full protective clothing and self-contained breathing apparatus.



6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures

No specific measures recommended.

Environmental Precautions

Prevent the material from entering drains or watercourses.

Methods and materials for containment and cleaning up

Pick up and dispose of in accordance with all applicable local and national regulations. Prevent the material from entering drains or watercourses.

7. HANDLING AND STORAGE

Precautions for safe handling

Wear appropriate protective clothing.

Conditions for safe storage

Store in original container at temperatures between 68°F and 77°F (20°C - 25°C). Store away from children and pets.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Control parameters

Exposure limits are listed below, if they exist.

Appropriate engineering controls

No specific measures necessary. Good general room ventilation is expected to be adequate to control airborne levels.

Individual protection measures

Respiratory Protection

Not required under normal conditions of use.

Skin Protection

Not required under normal conditions of use.

Eye/Face Protection

Not required under normal conditions of use.

Body Protection

Normal work wear

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance

Physical State	Solid (tablet)
Color	Off-white to tan

Odor	None
Odor Threshold	No data available
pH	No data available
Relative Density	No data available
Boiling Range/Point (°C/F)	No data available
Melting Point (°C/F)	No data available
Flash Point (PMCC) (°C/F)	Not flammable
Vapor Pressure	No data available



9. PHYSICAL AND CHEMICAL PROPERTIES

Evaporation Rate (BuAc=1)	No data available
Solubility in Water	No data available
Vapor Density (Air = 1)	No data available
VOC	No data available
Partition coefficient (n-octanol/water)	Not applicable
Viscosity	Not applicable
Auto-ignition Temperature	No data available
Decomposition Temperature	No data available
Upper explosive limit	No data available
Lower explosive limit	No data available
Flammability (solid, gas)	No data available

10. STABILITY AND REACTIVITY

Reactivity

Data is not available

Chemical Stability

Stable under normal conditions.

Possibility of hazardous reactions

Hazardous polymerization will not occur.

Conditions to Avoid

Heat - high temperatures

Incompatible Materials

None known.

Hazardous Decomposition Products

Oxides of carbon – nitrogen oxides

11. TOXICOLOGICAL INFORMATION

Acute Toxicity

Clindamycin Hydrochloride

Oral LD50 (rat) 2619 mg/kg

Specific Target Organ Toxicity (STOT) – single exposure

Clindamycin: Ingestion of large quantities of this material may cause gastrointestinal effects such as nausea, vomiting, diarrhea, and abdominal cramps.

Specific Target Organ Toxicity (STOT) – repeat exposure

Clindamycin: Ingestion at therapeutic doses can cause adverse gastrointestinal and liver effects.

Serious Eye damage/Irritation

Not an expected route of entry during normal handling and use.

Skin Corrosion/Irritation

Contact with skin is not expected to cause adverse effects.



11. TOXICOLOGICAL INFORMATION

Respiratory or Skin Sensitization

Clindamycin: Ingestion can cause allergic reaction in individuals hypersensitive to clindamycin and lincomycin.

Carcinogenicity

Not considered carcinogenic by NTP, IARC, and OSHA.

Germ Cell Mutagenicity

Clindamycin: Genotoxic effects of topical clindamycin were negative in the human lymphocyte chromosome aberration test and when evaluated with a rat micronucleus test and an Ames test.

Reproductive Toxicity

Clindamycin: Reproduction studies performed in rats and mice using oral doses of clindamycin up to 600 mg/kg/day (3.2 and 1.6 times the highest recommended adult human dose based on mg/m², respectively) or subcutaneous doses of clindamycin up to 250 mg/kg/day (1.3 and 0.7 times the highest recommended adult human dose based on mg/m², respectively) revealed no evidence of teratogenicity. There are, however, no adequate and well-controlled studies in pregnant women.

Clindamycin: FDA Category: B

(FDA Category B is defined as: Studies in laboratory animals have not demonstrated a fetal risk, but there are no controlled studies in pregnant women; or animal studies have shown an adverse effect (other than a decrease in fertility), but controlled studies in pregnant women have not demonstrated a risk to the fetus in the first trimester and there is no evidence of a risk in later trimesters.)

Aspiration Hazard

Not an aspiration hazard.

12. ECOLOGICAL INFORMATION

Ecotoxicity

No relevant studies identified.

Mobility in soil

No relevant studies identified.

Persistence/Degradability

No relevant studies identified.

Bioaccumulative Potential

No relevant studies identified.

Other adverse effects

No relevant studies identified.

13. DISPOSAL CONSIDERATIONS

Disposal Methods

Dispose of in accordance with all applicable local and national regulations.

14. TRANSPORT INFORMATION

Contact supplier for transport information.



15. REGULATORY INFORMATION

United States TSCA Inventory

This product is excluded from the US EPA Toxic Substance Control Act and is regulated under the Food, Drug and Cosmetic Act.

SARA Title III Sect. 311/312 Categorization

None

SARA Title III Sect. 313

The following chemicals are listed in Section 313 at or above de minimis concentrations: None

16. OTHER INFORMATION

Legend

ACGIH: American Conference of Governmental Industrial Hygienists

BOD: Biological Oxygen Demand

CAS#: Chemical Abstracts Service Number

FIFRA: Federal Insecticide, Fungicide and Rodenticide Act

IARC: International Agency for Research on Cancer

LC50: Lethal Concentration 50%

LD50: Lethal Dose 50%

N/A: Denotes no applicable information found or available

NTP: National Toxicology Program

OSHA: Occupational Safety and Health Administration

PEL: Permissible Exposure Limit

STEL: Short Term Exposure Limit

TLV: Threshold Limit Value

TSCA: Toxic Substance Control Act

Revision Date: March 2, 2020

Replaces: February 6, 2017

Changes made: Update to emergency numbers and section 15.

Information Source and References

This SDS is prepared by Hazard Communication Specialists based on information provided by internal company references.

Prepared By: EnviroNet LLC.

CLINTABS is a registered trademark of Virbac AH Inc.

The information and recommendations presented in this SDS are based on sources believed to be accurate. Virbac AH, Inc. assumes no liability for the accuracy or completeness of this information. It is the user's responsibility to determine the suitability of the material for their particular purposes. In particular, we make NO WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED, with respect to such information, and we assume no liability resulting from its use. Users should ensure that any use or disposal of the material is in accordance with applicable Federal, State, and local laws and regulations.